Log in
Enquire now
‌

US Patent 10421963 Oligonucleotide therapy for leber congenital amaurosis

Patent 10421963 was granted and assigned to ProQR Therapeutics on September, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
ProQR Therapeutics
ProQR Therapeutics
0
Current Assignee
ProQR Therapeutics
ProQR Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
104219630
Patent Inventor Names
Hee Lam Chan0
Patricia Coromoto Biasutto0
Date of Patent
September 24, 2019
0
Patent Application Number
155510260
Date Filed
February 26, 2016
0
Patent Citations Received
‌
US Patent 11920132 Oligonucleotide therapy for Leber congenital amaurosis
0
Patent Primary Examiner
‌
Ekaterina Poliakova-Georgantas
0
Patent abstract

Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10421963 Oligonucleotide therapy for leber congenital amaurosis

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.